The abstract is read at the publisher; the summary is JClub's.
CD40 agonist therapy improves survival in B2m-null melanoma models by engaging inflammatory monocytes and IFN-γ–dependent tumor control, with efficacy requiring CD8+ T cells and NK cells.
- Why it matters: Resistance to anti-PD-1 therapy limits long-term responses in melanoma, and antigen-presentation loss via B2m-null tumors is linked to immune evasion.
- What they did: Using single-cell RNA-seq, flow cytometry, and ex vivo assays, the study tested anti-PD-1 or CD40 agonist in antigen-presentation-deficient tumors and analyzed published human datasets for inflammatory monocyte signatures.
- The result: CD40 agonist reduced tumor growth and improved survival in B2m-null models; IFN-γ secretion was required, IFNγ receptor expression on host cells mattered, and an inflammatory monocyte signature associated with better ICI outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.